Investor Presentaiton
•
•
•
•
6
1234
1. Source: US: SHA Medical and Pharmacy Claims data, June 2022
2.
3.
Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate to severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226.
Forecast in USD given for reference using full-year FY2022 FX rate assumption of 132.4 JPY/USD
4. Source: US: SHA Medical and Pharmacy Claims data, June 2022; EUCAN: Internal estimate; Japan: Japan Medical Data Center, June 2022
BN JPY
800
700
600
500
400
300
200
ENTYVIO REVENUE
JPY 721.0B
USD $5.4B
35%
30%
25%
20%
15%
10%
5%
0%
100
0
FY14
FY15
FY16
FY17 FY18
FY19
FY20
FY21
FY22
(Forecast³)
Strong uptake of SC formulation in Europe & Canada
Outstanding Growth Momentum
Gut-selective alpha4beta7 integrin antagonist
#1 prescribed biologic in IBD bio-naïve patients in the U.S."
Head-to-head superiority versus adalimumab in UC²
1
>9 yrs of patient experience supports favorable safety profile
•
Jun-14
Sep-14
Dec-14
US Overall Share UC
... US Overall Share CD
Mar-15
Jun-15
Sep-15
Dec-15
Mar-16
Jun-16
Sep-16
Dec-16
Mar-17
Jun-17
Sep-17
Dec-17
EUCAN Overall Share UC
EUCAN Overall Share CD
Mar-18
Jun-18
Sep-18
Dec-18
Mar-19
% OF PATIENTS RECEIVING ENTYVIO4
Jun-19
Sep-19
Dec-19
Mar-20
Jun-20
Japan Overall Share CD
Japan Overall Share UC
Sep-20
SC formulation regulatory filing in U.S. expected in FY2023
Continuing to invest in further evidence generation
•
Biologics market continues to expand globally
•
ENTYVIO total patient share still increasing
Entyvio Peak Sales Estimate Raised to USD $7.5-9.0B
Raised Peak Sales Reflect Growth Opportunity
• Revised assumption on biosimilar entry timing
High unmet patient need remains in IBD
Dec-20
Mar-21
Jun-21
Sep-21
Dec-21
Mar-22
Jun-22
21.5%
19.6%
16.2%
28.8%
36.3%
3.7%
TakedaView entire presentation